ERBB2 and ductal breast carcinoma in situ: The amplification or overexpression of the tyrosine kinase receptor ErbB2 accounts for approximately 20% of all breast cancers1, and ErbB2 amplification is detected in about 50% of ductal carcinomas in situ (DCIS) of the mammary gland2.